SEPN logo

SEPN Septerna Inc

NASDAQ · Biotechnology · Healthcare

$39.45
-0.57 (-1.42%)

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 n…

Market Cap: $1.88Bsepterna.com

Price

No data yet.

Social Signal Score

29
5d
—
30d
30
4 mentions
—
60d
30
4 mentions
—
90d
26
5 mentions
—
news: 5

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 1Buy 9Hold 0Sell 0Strong Sell 0
Avg price target$50.4+27.8%
Low $43Median $49High $60
Current Consensus

Revenue

$18.88M+57115.15%
$33.0K$8.94M$17.84M$26.75M
Sep 2023Sep 2026

Analyst Estimates

FY2025
$-1.12
$-1.32–$-0.97
5 analysts
FY2026
$-1.48
$-1.98–$-1.18
6 analysts
FY2027
$-2.31
$-3.66–$-1.39
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jeffrey T. Finer
Sector
Healthcare
Industry
Biotechnology
Employees
134
Beta
2.20
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
6.04
septerna.com